Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments.
Hideki NawaTakahiro NiimuraKenta YagiMitsuhiro GodaYoshito ZamamiKeisuke IshizawaPublished in: Cancer reports (Hoboken, N.J.) (2021)
Treatment with abemaciclib and palbociclib is associated with a potential complication of interstitial lung disease, regardless of age.